• Recent
  • Class
  • Inventors
  • Assignees
  • Top Lists
  • Pricing
  • Account
Patents-Review.com
  1. Home
  2. Inventor
  3. A
  4. Ame…
  5. AMENDOLA Mario
🔗 Permalink
Inventor profile of:

Mario AMENDOLA

City:

Evry

Country:

France

Published Applications:

4

Last publication date:

2023-11-09

Recent patent applications by AMENDOLA Mario

Mario AMENDOLA from Evry, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-11-09
US20230357769A1
Chemistry; metallurgy

BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE

#2 | 2022-06-16
US20220184137A1
Human necessities

Correction of Beta-Thalassemia Phenotype by Genetically Engineered Hematopoietic Stem Cell

#3 | 2022-05-26
US20220160788A1
Human necessities

BIFUNCTIONAL VECTORS ALLOWING BCL11A SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF B-HEMOGLOBINOPATHIES

#4 | 2022-01-20
US20220017919A1
Chemistry; metallurgy

RECOMBINANT VECTORS SUITABLE FOR THE TREATMENT OF IPEX SYNDROME

InventorID:

5301554 ⎘

  1. Home
  2. Inventor
  3. A
  4. Ame…
  5. AMENDOLA Mario

Some parts © 2022-2026 Patents-Review.com

Browse & Discovery
  • Home
  • Patent Classification
  • Inventor Index
  • Assignee Index
  • Interesting Applications
Search & Tools
  • Basic Search
  • Advanced Search
  • Patent Alerts
  • Top Lists
  • Statistics
Information & Resources
  • About US Patent System
  • Terms & Privacy
  • Pricing
  • Contact
Quick Access
  • Latest Applications
  • Top Inventors 2026
  • Top Assignees 2026
  • Featured Patents
Disclaimer: This website is intended for informational purposes only, and its content is based on public patent records. Please note that some sections of this website have been created or processed using machine learning models. We provide content in good faith but make no guarantees regarding accuracy or completeness. By using this site, you accept any risks and waive claims against us for errors or omissions.